Regulatory - EBC46 Research Hub

Regulatory

FDA Botanical Drug Pathway: How IND Applications Shape the Future of EBC-46

The FDA botanical drug pathway offers a unique regulatory route for plant-derived compounds like EBC-46, with specific IND requirements that differ from synthetic drugs.

Regulatory

Accelerated Approval and EBC-46: Surrogate Endpoints, Biomarkers, and the Path to Conditional Clearance

The FDA's Accelerated Approval pathway could allow tigilanol tiglate to reach patients before full Phase III data is available — here's how surrogate endpoints make that possible.

Government regulatory building with columns symbolising drug approval pathways

EBC-46

Compassionate Use Pathways for Tigilanol Tiglate: How Patients May Access EBC-46 Before Full Approval

Compassionate use and expanded access programmes could allow terminal patients to receive tigilanol tiglate before regulatory approval is finalised.

Official government building representing pharmaceutical regulatory authority

EBC-46

Compassionate Use and Expanded Access for Tigilanol Tiglate: What Patients Need to Know

Expanded access programmes offer a potential pathway for cancer patients to receive tigilanol tiglate outside clinical trials — here is how the regulatory process works.

Regulatory documents and pharmaceutical approval frameworks for oncology drugs

EBC-46

Intratumoral Drug Approvals: How the Regulatory Framework Is Evolving for EBC-46

Drugs injected directly into tumours operate under different regulatory logic than systemic therapies. Here is how EBC-46 is navigating — and reshaping — that framework.

FDA government building representing drug approval regulatory pathway for oncology research

EBC-46

Stelfonta's FDA Approval: What It Means for Human Oncology Research

The FDA's full approval of Stelfonta validated tigilanol tiglate's PKC-activation mechanism for the first time, creating regulatory precedent that directly accelerates human oncology trials.

Government building columns representing regulatory authority and drug approval processes

EBC-46

Compassionate Use Pathways: How EBC-46 Could Reach Patients Before Full Approval

Regulatory frameworks for compassionate use and expanded access could allow tigilanol tiglate to reach patients with unmet needs well before Phase III completion.

FDA regulatory office documents representing Breakthrough Therapy Designation approval process

EBC-46

Breakthrough Therapy Designation: Could Tigilanol Tiglate Qualify and What Would It Mean?

Breakthrough Therapy Designation compresses development timelines dramatically. Here's how tigilanol tiglate stacks up against the FDA's criteria — and what qualifying would mean for patients.

Scales of justice in a modern government building symbolising regulatory oversight

EBC-46

Intratumoral Drug Approvals: The Unique Regulatory Challenges Facing EBC-46

Intratumoral drugs like tigilanol tiglate must satisfy regulatory requirements that conventional systemic cancer therapies were never designed to address — from injection site assessment to lesion-level endpoints.

European parliament building symbolising international regulatory frameworks for drug approval

EBC-46

EMA PRIME Designation: How Europe's Priority Medicines Programme Could Fast-Track EBC-46

The EMA's PRIME programme offers accelerated assessment and early dialogue for promising cancer therapies. Here is what that pathway could mean for tigilanol tiglate.

Medical regulatory documents and stethoscope representing FDA expanded access pathways for cancer drugs

EBC-46

Compassionate Use and Expanded Access: What They Mean for Tigilanol Tiglate Patients

Before a drug achieves full approval, compassionate use and expanded access programmes can provide a legal pathway for patients who have no other options. Here's how they apply to tigilanol tiglate.

Government regulatory building symbolising FDA and EMA drug approval pathways

EBC-46

Compassionate Use Pathways for Tigilanol Tiglate: How Patients Access Unapproved Cancer Drugs

Compassionate use and expanded access programmes could allow cancer patients to receive tigilanol tiglate before formal Phase III approval — here is how the regulatory framework works.

See all